

WEST

Generate Collection

Search Results - Record(s) 1 through 8 of 8 returned.

☐ 1. Document ID: US 20010041708 A1

L44: Entry 1 of 8

File: PGPB

Nov 15, 2001

PGPB-DOCUMENT-NUMBER: 20010041708

PGPB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010041708 A1

TITLE: Compositions for preventing cellulite in mammalian skin

PUBLICATION-DATE: November 15, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Halvorsen, Yuan-Di Chang	Holly Springs	NC	US	
Wilkison, William O.	Bahama	NC	US	
Lea-Currie, Yolanda Renee	Burlington	NC	US	
Pieraccini, Peter	Durham	NC	US	
Sen, Anindita	Cary	NC	US	

US-CL-CURRENT: 514/264; 424/59, 424/725, 514/560

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

☐ 2. Document ID: US 6303588 B1

L44: Entry 2 of 8

File: USPT

Oct 16, 2001

US-PAT-NO: 6303588

DOCUMENT-IDENTIFIER: US 6303588 B1

TITLE: Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor

DATE-ISSUED: October 16, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Danielov, Michael M.	Rego Park	NY	11374	

US-CL-CURRENT: 514/109; 514/103, 514/167, 514/171, 514/182, 514/305, 514/573

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	-----------	-------

☐ 3. Document ID: US 6004560 A

L44: Entry 3 of 8

File: USPT

Dec 21, 1999

US-PAT-NO: 6004560

DOCUMENT-IDENTIFIER: US 6004560 A

TITLE: Nasal spray (drop) for treating fever/cold, and its preparation

DATE-ISSUED: December 21, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hsu; Wu-Ching	Taipei			TWX
Keng; Su- Hsien	Taipei			TWX

US-CL-CURRENT: 424/773

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

PMC	Draw Desc	Image
-----	-----------	-------

☐ 4. Document ID: US 5885974 A

L44: Entry 4 of 8

File: USPT

Mar 23, 1999

US-PAT-NO: 5885974

DOCUMENT-IDENTIFIER: US 5885974 A

TITLE: Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor

DATE-ISSUED: March 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Danielov; Michael M.	Rego Park	NY	11374	

US-CL-CURRENT: 514/109; 514/103, 514/167, 514/171, 514/182, 514/305, 514/573,
514/724

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

PMC	Draw Desc	Image
-----	-----------	-------

☐ 5. Document ID: US 5667793 A

L44: Entry 5 of 8

File: USPT

Sep 16, 1997

US-PAT-NO: 5667793

DOCUMENT-IDENTIFIER: US 5667793 A

TITLE: Skin care compositions for treating cellulite

DATE-ISSUED: September 16, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cho; Suk Hyung.	Monroeville	PA		
Richardson; Norman Kramer	Rockaway Township	NJ		
Burger; Allan Robert	Passaic	NJ		
Brinker; Anita Marie	Midland Park	NJ		
Rerek; Mark Edward	Scotch Plains	NJ		

US-CL-CURRENT: 424/401; 424/773, 424/777, 514/937, 514/944

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KINC	Draw Desc	Images
------	-----------	--------

☐ 6. Document ID: US 5536499 A

L44: Entry 6 of 8

File: USPT

Jul 16, 1996

US-PAT-NO: 5536499

DOCUMENT-IDENTIFIER: US 5536499 A

TITLE: Cosmetic compositions for reducing or preventing signs of cellulite

DATE-ISSUED: July 16, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Znaiden; Alexander P.	Trumbull	CT		
Cheney; Michael C.	Fairfield	CT		
Slavtcheff; Craig S.	Cheshire	CT		
Cho; Suk H.	Bogota	NJ		

US-CL-CURRENT: 424/401; 514/860

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KINC	Draw Desc	Images
------	-----------	--------

☐ 7. Document ID: US 4557934 A

L44: Entry 7 of 8

File: USPT

Dec 10, 1985

US-PAT-NO: 4557934

DOCUMENT-IDENTIFIER: US 4557934 A

TITLE: Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one

DATE-ISSUED: December 10, 1985

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Eugene R.	Cincinnati	OH		

US-CL-CURRENT: 514/159; 424/449, 424/601, 514/165, 514/223.5, 514/224.2, 514/224.5, 514/226.8, 514/231.2, 514/233.2, 514/236.2, 514/270, 514/374, 514/399, 514/635, 514/947

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KINC	Draw Desc	Images
------	-----------	--------

☐ 8. Document ID: US 4537776 A

L44: Entry 8 of 8

File: USPT

Aug 27, 1985

US-PAT-NO: 4537776

DOCUMENT-IDENTIFIER: US 4537776 A

TITLE: Penetrating topical pharmaceutical compositions containing
N-(2-hydroxyethyl) pyrrolidone

DATE-ISSUED: August 27, 1985

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Eugene R.	Cincinnati	OH		

US-CL-CURRENT: 514/424; 514/171, 514/300, 514/549, 514/825, 514/826, 514/859

Full	Title	Claims	Front	Review	Classification	Date	Reference
------	-------	--------	-------	--------	----------------	------	-----------

SMC	Draw Desc	Image
-----	-----------	-------

[Generate Collection](#)

Terms	Documents
122 and 11	8

[Display](#)

100

Documents, starting with Document:

8

Display Format: [CIT](#)[Change Format](#)

WEST**Generate Collection****Search Results - Record(s) 1 through 1 of 1 returned.**☐ 1. Document ID: US 6235773 B1

L45: Entry 1 of 1

File: USPT

May 22, 2001

US-PAT-NO: 6235773

DOCUMENT-IDENTIFIER: US 6235773 B1

TITLE: Compositions for regulating skin appearance

DATE-ISSUED: May 22, 2001

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Bissett; Donald Lynn

Hamilton

OH

US-CL-CURRENT: 514/456; 514/455, 514/685**Full | Title | Citation | Front | Review | Classification | Date | Reference****KABC | Draw Desc | Image****Generate Collection****Terms**

I22 and I2

Documents

1

Display**100** Documents, starting with Document: **1****Display Format:** **CIT****Change Format**

WEST

Generate Collection

Search Results - Record(s) 1 through 8 of 8 returned.

☐ 1. Document ID: US 6284802 B1

L46: Entry 1 of 8

File: USPT

Sep 4, 2001

US-PAT-NO: 6284802

DOCUMENT-IDENTIFIER: US 6284802 B1

TITLE: Methods for regulating the condition of mammalian keratinous tissue

DATE-ISSUED: September 4, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bissett; Donald Lynn	Hamilton	OH		
Jewell-Motz; Elizabeth Ann	Cincinnati	OH		

US-CL-CURRENT: 514/739; 514/159, 514/2, 514/356, 514/725[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#)[HMAC](#) [Draw Desc](#) [Image](#)☐ 2. Document ID: US 6251863 B1

L46: Entry 2 of 8

File: USPT

Jun 26, 2001

US-PAT-NO: 6251863

DOCUMENT-IDENTIFIER: US 6251863 B1

TITLE: Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin

DATE-ISSUED: June 26, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yue; Samuel K.	Edina	MN	55435	

US-CL-CURRENT: 514/12; 514/2, 530/324[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#)[HMAC](#) [Draw Desc](#) [Image](#)☐ 3. Document ID: US 6001366 A

L46: Entry 3 of 8

File: USPT

Dec 14, 1999

US-PAT-NO: 6001366

DOCUMENT-IDENTIFIER: US 6001366 A

TITLE: Slimming cosmetic composition containing a Chrysanthellum indicum extract

DATE-ISSUED: December 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vacher; Anne-Marie	Le Chesnay			FRX
Fritsch; Marie-Claire	Paris			FRX

US-CL-CURRENT: 424/729; 424/195.17, 424/400, 424/401, 424/752, 424/764, 424/777

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

PMAC	Draw Desc	Image
------	-----------	-------

☐ 4. Document ID: US 5523090 A

L46: Entry 4 of 8

File: USPT

Jun 4, 1996

US-PAT-NO: 5523090

DOCUMENT-IDENTIFIER: US 5523090 A

TITLE: Skin treatment composition

DATE-ISSUED: June 4, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Znaiden; Alexander P.	Trumbull	CT		
Slavtcheff; Craig S.	Cheshire	CT		
Cheney; Michael C.	Fairfield	CT		

US-CL-CURRENT: 424/401; 514/846, 514/860, 514/944

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

PMAC	Draw Desc	Image
------	-----------	-------

☐ 5. Document ID: US 5436230 A

L46: Entry 5 of 8

File: USPT

Jul 25, 1995

US-PAT-NO: 5436230

DOCUMENT-IDENTIFIER: US 5436230 A

TITLE: Use of a growth factor in a slimming composition

DATE-ISSUED: July 25, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Soudant; Etienne	Fresnes			FRX
Nadaud; Jean-Francois	Paris			FRX

US-CL-CURRENT: 514/21; 514/12

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

PMAC	Draw Desc	Image
------	-----------	-------

☐ 6. Document ID: DE 4401308 A1

L46: Entry 6 of 8

File: EPAB

Jul 20, 1995

PUB-NO: DE004401308A1

DOCUMENT-IDENTIFIER: DE 4401308 A1

TITLE: Cosmetic compsn. with anti-cellulite and slimming activity

PUBN-DATE: July 20, 1995

INVENTOR-INFORMATION:

NAME

COUNTRY

VOS, HARALD PROF DR

DE

DEPPE, MARC

DE

DEPPE, RAPHAELA

DE

INT-CL (IPC): A61K 7/48

EUR-CL (EPC): A61K007/48; A61K007/48, A61K007/48 , A61K007/48 , A61K007/48 ,
A61K007/48 , A61K007/48

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KMCC	Draw Desc	Image
------	-----------	-------

☐ 7. Document ID: DE 4401308 C2, DE 4401308 A1

L46: Entry 7 of 8

File: DWPI

Jan 30, 1997

DERWENT-ACC-NO: 1995-264208

DERWENT-WEEK: 199709

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Cosmetic compsn. with anti-cellulite and slimming activity - comprises
plant- and peptide extract, muco-poly:saccharide ester(s), cell metabolism
activating complex and metabolic prod. draining complex

INVENTOR: DEPPE, M; DEPPE, R ; VOSS, H

PRIORITY-DATA: 1994DE-4401308 (January 18, 1994)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

DE 4401308 C2 January 30, 1997

012

A61K007/48

DE 4401308 A1 July 20, 1995

009

A61K007/48

INT-CL (IPC): A61K 7/48; A61K 35/78

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KMCC	Draw Desc	Image
------	-----------	-------

☐ 8. Document ID: IT 1217516 B

L46: Entry 8 of 8

File: DWPI

Mar 22, 1990

DERWENT-ACC-NO: 1992-067087
DERWENT-WEEK: 199209
COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Carnitine and its derivs. for cellulite treatment - NoAbstract

PRIORITY-DATA: 1988IT-0020483 (May 6, 1988)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
IT 1217516 B	March 22, 1990		000	

INT-CL (IPC): A61K 0/00

Full	Title	Citation	Front	Review	Classification	Date	Reference	KWC	Draw Descr	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----	------------	-------

Generate Collection

Terms	Documents
l22 and l3	8

Display

100 Documents, starting with Document:

8

Display Format:

CIT

Change Format

WEST

Generate Collection

Search Results - Record(s) 1 through 12 of 12 returned.

☐ 1. Document ID: US 4938962 A

L48: Entry 1 of 12

File: USPT

Jul 3, 1990

US-PAT-NO: 4938962

DOCUMENT-IDENTIFIER: US 4938962 A

TITLE: Heterogeneous topical compositions having a base of microgranules of caffeine and/or its derivatives, which can be used as slenderizer and/or in the treatment of cellulitis, as well as their preparation

DATE-ISSUED: July 3, 1990

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Trebosc; Marie-Therese	Castres			FRX
Cousse; Henri	Castres			FRX
Mouzin; Gilbert	Toulouse			FRX

US-CL-CURRENT: 424/439; 424/489, 424/490

Full Title Citation Front Review Classification Date Reference

KINC Draw Desc Image

☐ 2. Document ID: US 4938962 A

L48: Entry 2 of 12

File: EPAB

Jul 3, 1990

PUB-NO: US004938962A

DOCUMENT-IDENTIFIER: US 4938962 A

TITLE: Heterogeneous topical compositions having a base of microgranules of caffeine and/or its derivatives, which can be used as slenderizer and/or in the treatment of cellulitis, as well as their preparati

PUBN-DATE: July 3, 1990

INVENTOR-INFORMATION:

NAME	COUNTRY
TREBOSC, MARIE-THERESE	FR
COUSSE, HENRI	FR
MOUZIN, GILBERT	FR

INT-CL (IPC): A61K 47/00

EUR-CL (EPC): A61K007/00; A61K007/48, A61K009/06, A61K031/52

Full Title Citation Front Review Classification Date Reference

KINC Draw Desc Image

☐ 3. Document ID: WO 200139740 A1, FR 2801786 A1

L48: Entry 3 of 12

File: DWPI

Jun 7, 2001

DERWENT-ACC-NO: 2001-374661

DERWENT-WEEK: 200139

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Topical compositions containing Idazoxan and caffeine useful for slimming
and for the treatment of cellulite

INVENTOR: BORDAT, P; COUSSE, H ; FABRE, P ; TREBOSC, M T ; TREBOSC, M

PRIORITY-DATA: 1999FR-0015141 (December 1, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200139740 A1	June 7, 2001	F	022	A61K007/48
FR 2801786 A1	June 8, 2001		000	A61K007/48

INT-CL (IPC): A61K 7/48

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KMC	Draw Desc	Image
-----	-----------	-------

☐ 4. Document ID: EP 1146844 A1, WO 200045774 A1

L48: Entry 4 of 12

File: DWPI

Oct 24, 2001

DERWENT-ACC-NO: 2000-524347

DERWENT-WEEK: 200171

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Membrane lipid-containing composition comprising xanthine and/or carboxylic
acid active agent gives enhanced delivery of e.g. caffeine for treating cellulite

INVENTOR: LEIGH, M L S; LEIGH, S ; THOMPSON, C M

PRIORITY-DATA: 1999GB-0002527 (February 4, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1146844 A1	October 24, 2001	E	000	A61K007/00
WO 200045774 A1	August 10, 2000	E	022	A61K007/00

INT-CL (IPC): A61K 7/00; A61K 7/48; A61P 17/00

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KMC	Draw Desc	Image
-----	-----------	-------

☐ 5. Document ID: DE 19901502 C1, EP 1020192 A2

L48: Entry 5 of 12

File: DWPI

Sep 21, 2000

DERWENT-ACC-NO: 2000-453755
DERWENT-WEEK: 200047
COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Composition useful for cosmetic treatment of cellulite or as a medicament comprises theophylline, furosemide, carbazochrome and lidocaine and/or procaine

INVENTOR: SCHNEIDER, M; WIRSIG, D

PRIORITY-DATA: 1999DE-1001502 (January 11, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 19901502 C1	September 21, 2000		000	A61K031/52
EP 1020192 A2	July 19, 2000	G	005	A61K031/70

INT-CL (IPC): A61K 31/165; A61K 31/167; A61K 31/52; A61K 31/635; A61K 31/70; A61P 3/04; A61K 31/70; A61K 31/165; A61K 31/167; A61K 31/52; A61K 31/635

Full Title Citation Front Review Classification Date Reference

PMC Draw Desc Image

☐ 6. Document ID: WO 9717056 A1, FR 2740681 A1

L48: Entry 6 of 12

File: DWPI

May 15, 1997

DERWENT-ACC-NO: 1997-280787
DERWENT-WEEK: 199725
COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Cosmetic composition comprises caffeine and extract of viburnum bark or leaves - useful in combating free radicals and in treatment of cellulite

INVENTOR: FABRE, B; TREBOSC, M T ; TREBOSC, M

PRIORITY-DATA: 1995FR-0013136 (November 7, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9717056 A1	May 15, 1997	F	023	A61K007/48
FR 2740681 A1	May 9, 1997		014	A61K007/48

INT-CL (IPC): A61K 7/48

Full Title Citation Front Review Classification Date Reference

PMC Draw Desc Image

☐ 7. Document ID: DE 29612123 U1

L48: Entry 7 of 12

File: DWPI

Sep 12, 1996

DERWENT-ACC-NO: 1996-414018
DERWENT-WEEK: 199642
COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Transdermal gel for metabolising subcutaneous fat - contg. ephedrine, caffeine, salicyclic acid and DMSO

PRIORITY-DATA: 1996DE-2012123 (July 11, 1996)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 29612123 U1	September 12, 1996		004	A61K031/60

INT-CL (IPC): A61K 31/52; A61K 31/60

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 8. Document ID: IT 1263754 B

L48: Entry 8 of 12

File: DWPI

Aug 29, 1996

DERWENT-ACC-NO: 1997-135163
DERWENT-WEEK: 199713
COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Cellulite and localised fat treatment compsn. - based on ephedrine and .
caffeine NoAbstract

PRIORITY-DATA: 1991IT-B000490 (December 20, 1991)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
IT 1263754 B	August 29, 1996		000	A61K000/00

INT-CL (IPC): A61K 0/00

Full	Title	Citation	Front	Review	Classification	Date	Reference
------	-------	----------	-------	--------	----------------	------	-----------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 9. Document ID: WO 9211838 A1, DE 4290049 T, FR 2671487 A1, JP 06506668 W, US 5436230 A

L48: Entry 9 of 12

File: DWPI

Jul 23, 1992

DERWENT-ACC-NO: 1992-268372
DERWENT-WEEK: 199232
COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Slimming compen. contg. growth factor as lipolytic agent - opt. together with caffeine, esp. for control of cellulite by topical or oral application

INVENTOR: NADAUD, J; SOUDANT, E ; NADAUD, J F

PRIORITY-DATA: 1991FR-0000324 (January 14, 1991)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9211838 A1	July 23, 1992	F	019	A61K007/48
DE 4290049 T	January 13, 1994		000	A61K007/48
FR 2671487 A1	July 17, 1992		016	A61K007/48
JP 06506668 W	July 28, 1994		000	A61K037/24
US 5436230 A	July 25, 1995		007	A61K031/00

INT-CL (IPC): A61K 7/00; A61K 7/48; A61K 31/00; A61K 31/175; A61K 31/245; A61K 31/48; A61K 37/24; A61K 37/36

Full Title Citation Front Review Classification Date Reference FWC Draw Desc Image

☐ 10. Document ID: EP 371874 A, CA 2004092 A, FR 2639541 A, JP 03170430 A, US 5030451 A

L48: Entry 10 of 12

File: DWPI

Jun 6, 1990

DERWENT-ACC-NO: 1990-173214
DERWENT-WEEK: 199023
COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Organic-based caffeine carboxylate(s) - used in the treatment of fibrosis

INVENTOR: COUSSE, H; MOUZIN, G ; TREBOSC, M T

PRIORITY-DATA: 1988FR-0015575 (November 29, 1988), 1989JP-0308822 (November 28, 1989)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 371874 A	June 6, 1990		000	
CA 2004092 A	May 29, 1990		000	
FR 2639541 A	June 1, 1990		000	
JP 03170430 A	July 24, 1991		000	
US 5030451 A	July 9, 1991		000	

INT-CL (IPC): A61K 7/48; A61K 31/39; C07C 215/40; C07C 277/08; C07D 207/08; C07D 213/30; C07D 311/72; C07D 473/08; C07D 487/04

Full Title Citation Front Review Classification Date Reference FWC Draw Desc Image

☐ 11. Document ID: US 5658576 A, EP 371844 A, LU 87390 A, JP 02180827 A, EP 371844 B1, DE 68902304 E

L48: Entry 11 of 12

File: DWPI

Aug 19, 1997

DERWENT-ACC-NO: 1990-173185

DERWENT-WEEK: 199739

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Caffeine-like lipolytic compsns. for slimming or cosmetics - contg. (mixt. of) alpha-tocopherol acetate or alpha-tocopherol-, benzyl-xanthinol - or hexyl-nicotinate(s)

INVENTOR: SOUDANT, E

PRIORITY-DATA: 1988LU-0087390 (November 17, 1988), 1994US-0307071 (September 16, 1994)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 5658576 A	August 19, 1997		005	A61K007/00
EP 371844 A	June 6, 1990		000	
LU 87390 A	June 12, 1990		000	
JP 02180827 A	July 13, 1990		000	
EP 371844 B1	July 29, 1992	F	008	A61K007/48
DE 68902304 E	September 3, 1992		000	A61K007/48

INT-CL (IPC): A61K 7/00; A61K 7/48; A61K 9/00; A61K 31/355; A61K 31/45; A61K 31/455; C07D 213/80

Full Title Citation Front Review Classification Date Reference

KWIC Draw Desc Image

☐ 12. Document ID: EP 323294 A, FR 2624010 A, US 4938962 A

L48: Entry 12 of 12

File: DWPI

Jul 5, 1989

DERWENT-ACC-NO: 1989-194587

DERWENT-WEEK: 198927

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Heterogeneous topical compsns. contg. caffeine carboxylate salt - in gel base, for treating cellulitis and to promote slimming

INVENTOR: COUSSE, H; MOUZIN, G ; TREBOSC, M T

PRIORITY-DATA: 1987FR-0016969 (December 7, 1987)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 323294 A	July 5, 1989	F	007	
FR 2624010 A	June 9, 1989		000	
US 4938962 A	July 3, 1990		000	

INT-CL (IPC): A61K 7/48; A61K 47/00

Full Title Citation Front Review Classification Date Reference

KWIC Draw Desc Image

[Generate Collection](#)

Terms	Documents
l22 and l4.ti.	12

[Display](#)[100](#)

Documents, starting with Document:

[12](#)**Display Format:**[CIT](#)[Change Format](#)

WEST[Generate Collection](#)**Search Results - Record(s) 1 through 1 of 1 returned.**☐ 1. Document ID: US 5514374 A

L49: Entry 1 of 1

File: USPT

May 7, 1996

US-PAT-NO: 5514374

DOCUMENT-IDENTIFIER: US 5514374 A

TITLE: Cosmetic or pharmaceutical composition containing a black horehound extract

DATE-ISSUED: May 7, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bonte; Frederic	Courbevoie			FRX
Meybeck; Alain	Courbevoie			FRX
Dumas; Marc	Colombes			FRX

US-CL-CURRENT: 424/745; 424/63, 424/70.6, 424/742, 424/78.03, 514/558[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#)[NMC](#) | [Draw Data](#) | [Image](#)[Generate Collection](#)

Terms	Documents
122 and 15	1

[Display](#)Documents, starting with Document: **Display Format:** [Change Format](#)

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)**Search Results -**

Terms	Documents
122 and 15	1

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index

Database: IBM Technical Disclosure Bulletins**Refine Search:**

122 and 15

[Clear](#)**Search History****Today's Date: 1/17/2002**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI	122 and 15	1	L47
USPT,PGPB,JPAB,EPAB,DWPI	122 and 14.ti.	12	L46
USPT,PGPB,JPAB,EPAB,DWPI	122 and 14	111	L45
USPT,PGPB,JPAB,EPAB,DWPI	122 and 13	8	L44
USPT,PGPB,JPAB,EPAB,DWPI	122 and 12	1	L43
USPT,PGPB,JPAB,EPAB,DWPI	122 and 11	8	L42
USPT,PGPB,JPAB,EPAB,DWPI	122 and (14 and 15 and 11)	0	L41
USPT,PGPB,JPAB,EPAB,DWPI	122 and (14 and 15 and 12)	0	L40
USPT,PGPB,JPAB,EPAB,DWPI	122 and (14 and 15)	1	L39
USPT,PGPB,JPAB,EPAB,DWPI	122 and (13 and 14 and 15)	0	L38
USPT,PGPB,JPAB,EPAB,DWPI	122 and (13 and 14 and 11)	0	L37
USPT,PGPB,JPAB,EPAB,DWPI	122 and (13 and 14)	4	L36
USPT,PGPB,JPAB,EPAB,DWPI	122 and (12 and 13)	0	L35
USPT,PGPB,JPAB,EPAB,DWPI	122 and (12 and 14)	1	L34

USPT,PGPB,JPAB,EPAB,DWPI	l22 and (l2 and l5)	0	L33
USPT,PGPB,JPAB,EPAB,DWPI	l22 and (l1 and l5)	0	L32
USPT,PGPB,JPAB,EPAB,DWPI	l22 and (l1 and l4 and l5)	0	L31
USPT,PGPB,JPAB,EPAB,DWPI	l22 and (l1 and l4 and l3)	0	L30
USPT,PGPB,JPAB,EPAB,DWPI	l22 and (l1 and l4)	5	L29
USPT,PGPB,JPAB,EPAB,DWPI	l22 and (l1 and l3)	0	L28
USPT,PGPB,JPAB,EPAB,DWPI	l22 and (l1 and l2)	0	L27
USPT,PGPB,JPAB,EPAB,DWPI	l22 and (l1 and l2 and l3)	0	L26
USPT,PGPB,JPAB,EPAB,DWPI	l22 and (l1 and l2 and l3 and l4)	0	L25
USPT,PGPB,JPAB,EPAB,DWPI	l22 and (l1 and l2 and l3 and l4 and l5)	0	L24
USPT,PGPB,JPAB,EPAB,DWPI	l22 and (l1 or l2 or l3 or l4 or l5)	118	L23
USPT,PGPB,JPAB,EPAB,DWPI	cellulit\$	1032	L22
USPT,PGPB,JPAB,EPAB,DWPI	l5 and (topical or cellulite)	14	L21
USPT,PGPB,JPAB,EPAB,DWPI	l10 and (topical or cellulite)	28	L20
USPT,PGPB,JPAB,EPAB,DWPI	l9 and cellulite	1	L19
USPT,PGPB,JPAB,EPAB,DWPI	l9 and topical	39	L18
USPT,PGPB,JPAB,EPAB,DWPI	l14 and cellu\$	6	L17
USPT,PGPB,JPAB,EPAB,DWPI	l14 and cellu\$	6	L16
USPT,PGPB,JPAB,EPAB,DWPI	l14 and cellu\$	6	L15
USPT,PGPB,JPAB,EPAB,DWPI	l13.ti.	66	L14
USPT,PGPB,JPAB,EPAB,DWPI	genistein or diadzein or biochanin\$ or daidzein	671	L13
USPT,PGPB,JPAB,EPAB,DWPI	l7 and celluli\$	0	L12
USPT,PGPB,JPAB,EPAB,DWPI	l5.ti.	10	L11
USPT,PGPB,JPAB,EPAB,DWPI	l4.ti.	1412	L10
USPT,PGPB,JPAB,EPAB,DWPI	l3.ti.	1086	L9
USPT,PGPB,JPAB,EPAB,DWPI	l2.ti.	58	L8
USPT,PGPB,JPAB,EPAB,DWPI	l1.ti.	163	L7
USPT,PGPB,JPAB,EPAB,DWPI	l1 and l2 and l3 and l4 and l5	0	L6
USPT,PGPB,JPAB,EPAB,DWPI	forskohlii or makandi	64	L5
USPT,PGPB,JPAB,EPAB,DWPI	theophylline or caffeine or theobromine	10822	L4
USPT,PGPB,JPAB,EPAB,DWPI	\$carnitine	2377	L3
USPT,PGPB,JPAB,EPAB,DWPI	genistein or diadzein or biochanin\$	626	L2
USPT,PGPB,JPAB,EPAB,DWPI	quercetin or fisetin	1165	L1

PALM INTRANETDay : Thursday
Date: 1/17/2002
Time: 16:53:00**Patent Number Information**Application Number: 09/386235**Assignments**Filing Date: **08/31/1999**Application Received: **08/31/1999**Patent Number: **6309656**Issue Date: **10/30/2001**Date of Abandonment: **00/00/0000**

Attorney Docket Number:

Status: **150 / PATENTED CASE**Confirmation Number: **1186**Title of Invention: **COSMETIC AND SKIN PROTECTIVE COMPOSITIONS**Examiner Number: **78176 / HAGHIGHATIAN, MINA**Group Art Unit: **1619**Class/Subclass: **424/401.000**Lost Case: **NO**

Interference Number:

Unmatched Petition:

L&R CodeStatus Date: **10/11/2001**

Bar Code	Location	Location Date	Chrg to Loc	Charge to Name	Emp. ID	Infra Loc
09386235	9200	01/11/2002	1616	No Charge to Name	DDAVIS6	

**Appln
Info**[Contents](#)[Petition Info](#)[Atty/Agent Info](#)[Continuity Data](#)[Foreign Data](#)[Invento](#)Search Another: Application# or Patent# PCT / / or PG PUBS # Attorney Docket #

(To Go BACK Use BACK Button on Your BROWSER Tool Bar)

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page

**25% Off***30 count box***\$14.99***Our Price***\$11.25**

French Parad'ox

The benefits of red wine without the alcohol

French Parad'ox is a major breakthrough for those who want the benefits of red wine but don't want to or can't tolerate alcohol. French Parad'ox is a special red wine marc extract in capsule form. Each capsule contains an amount of antioxidant polyphenols equivalent to the amount in two glasses of red wine - minus the alcohol.

French Parad'ox is more complete than other 'grape extract' products because it contains more than just a grape seed extract. It also contains extracts from the skin and leaves. Resveratrol, the most studied antioxidant of red wine, is found in grape skins, not in seeds. French Parad'ox is standardized to contain .02% resveratrol, plus 25% anthocyanosides, considered to be among the most potent antioxidants yet discovered. 100% vegetarian




25% Off

30 count box

~~\$17.99~~

Our Price

\$13.50



GMO-Free PhytoSoya Soy phytoestrogens for hormonal balance*

With 35 mg isoflavones per capsule, PhytoSoya is a one-per-day soy supplement. Isoflavones are natural plant estrogens that may help ease symptoms of menopause and which may help maintain a healthy heart.

General recommendations for soy isoflavone intake are based on the typical Asian diet, which contains between 30 and 50 mg per day. PhytoSoya falls right into this recommended range with 35 mg per capsule. Each capsule contains approximately 5.5 mg genistein (-in), 18 mg daidzein (-in) and 11.5 mg glycitein (-in). 100% vegetarian.

**U.S. Trademark Electronic Search System (TESS)**

TESS was last updated on Thu Jan 17 04:30:59 EST 2002

[PTO HOME](#) [TRADEMARK](#) [TESS HOME](#) [NEW USER](#) [STRUCTURED](#) [FREE FORM](#) [BROWSE DICT](#) [BOTTOM](#) [HELP](#)



Please logout when you are done to release system resources allocated for you.

Record 1 out of 1

Check Status

(TARR contains current status, correspondence address and attorney of record for this mark. Use the "Back" button of the Internet Browser to return to TESS)

Typed Drawing

Word Mark	DERMALEAN
Goods and Services	IC 005. US 006 018 044 046 051 052. G & S: VITAMIN AND MINERAL FOOD SUPPLEMENTS
Mark Drawing Code	(1) TYPED DRAWING
Serial Number	75855039
Filing Date	December 8, 1999
Filed ITU	FILED AS ITU
Published for Opposition	August 8, 2000
Owner	(APPLICANT) IMPACT Nutrition, Inc. CORPORATION COLORADO 9928 E. Alabama Drive #1725 Denver COLORADO 80231
Type of Mark	TRADEMARK
Register	PRINCIPAL
Live/Dead Indicator	LIVE

[PTO HOME](#) [TRADEMARK](#) [TESS HOME](#) [NEW USER](#) [STRUCTURED](#) [FREE FORM](#) [BROWSE DICT](#) [TOP](#) [HELP](#)

This is Google's cache of <http://www.gnc.com/wellness/natpharm/Herb/Coleus.htm>.
 Google's cache is the snapshot that we took of the page as we crawled the web.
 The page may have changed since that time. Click here for the [current page](#) without highlighting.

Google is not affiliated with the authors of this page nor responsible for its content.

These search terms have been highlighted: **coleus forskohlii**



[Home](#) [The Natural Pharmacy](#) [GNC Difference](#) [GNC Gold Card Club](#) [Store Locator](#)

[Health Concerns](#) | [Nutritional Supplements](#) | [Herbal Remedies](#) | [Homeopathic Remedies](#) | [Drug Interactions](#) | [Diets & Therapies](#)

Coleus (*Coleus forskohlii*)

Common name: Makandi

Parts used and where grown: This attractive, perennial member of the mint (Lamiaceae) family originated in the lower elevations of India. It is now grown around the world as an ornamental plant. The root is used medicinally.

Coleus has been used in connection with the following conditions (refer to the individual health concern for complete information):

Ranking	Health Concerns
Secondary	Asthma
	Glaucoma
Other	Cardiomyopathy
	Hypertension
	Obesity
	Psoriasis

Historical or traditional use (may or may not be supported by scientific studies): As recorded in ancient Sanskrit texts, **coleus** was used to treat heart and lung diseases, intestinal spasms, [insomnia](#), and convulsions in [Ayurvedic](#) medicine.¹ These show striking similarities to the actions modern scientific studies have shown. However, there appears to be no pre-modern mention of the use of **coleus** for [glaucoma](#).

Active constituents: Forskolin is a diterpene found in **coleus** that inhibits the enzyme adenylate cyclase.² Adenylate cyclase regulates formation of cAMP, a compound that in turn exerts control over numerous activities in every cell. Forskolin-induced elevation of cAMP levels in cells leads to blood vessel dilation,³ inhibition of mast cells (and hence reduction in allergic inflammation),⁴ increase in thyroid hormone secretion,⁵ and stimulation of fat release from fat cells.⁶ Forskolin has other properties as well, including inhibition of the pro-inflammatory substance known as platelet-activating factor (PAF)⁷ and inhibition of the spread of cancer cells.⁸ Research into **coleus**'s other constituents has been sparse.

Much of the research into the actions of forskolin has primarily been completed in an attempt to understand how cAMP is involved in various disease processes. As a result, there has been little human study of the medicinal properties of **coleus**. Studies in healthy humans, including at least one double-blind study, have repeatedly shown that direct application of forskolin to the eyes lowers pressure in them.⁹ ¹⁰ Elevated eye pressure can lead to glaucoma.

One non-randomized study on humans has shown that forskolin can reduce blood pressure and improve heart function in people with cardiomyopathy.¹¹ Forskolin was given by injection in this study; it is unknown if oral **coleus** extracts would have the same effect. A small double-blind study found that inhaled forskolin could decrease lung spasms in asthmatics compared to placebo.¹²

How much is usually taken? **Coleus** extracts standardized to 18% forskolin are available, and 50–100 mg can be taken two to three times per day. Fluid extract can be taken in the amount of 2–4 ml three times per day.¹³ Most studies have used injected forskolin, so it is unclear if oral ingestion of **coleus** extracts will provide similar benefits in the amounts recommended above. Until topical preparations of pure forskolin are available for people with glaucoma, an eye bath can be prepared using the fluid extract. Boiled water is mixed with 4–8 drops of the fluid extract and applied directly to the eyes.¹⁴ It is imperative to maintain sterile conditions so as not to cause eye infections during this procedure.

Are there any side effects or interactions? **Coleus** is generally free from side effects. It should be avoided in people with ulcers, because it may increase stomach acid levels. It could also theoretically cause a problem in someone with low blood pressure, though this has not been documented. Direct application to the eyes may cause transitory tearing, burning, and itching. The safety of **coleus** in pregnancy and lactation is unknown.

Certain medications may interact with **coleus**. Refer to the drug interactions summary for a list of those medications. It is recommended you discuss the use of **coleus** and your current medication(s) with your doctor or pharmacist.

Within *The Natural Pharmacy*, information about the effects of a particular supplement or herb on a particular condition has been qualified in terms of the methodology or source of supporting data (for example: clinical, double blind, meta-analysis, or traditional use). For the convenience of the reader, the information in the table listing the supplements for particular conditions is also categorized. The criteria for the categorizations are: “Primary” indicates there are reliable and relatively consistent scientific data showing a health benefit. “Secondary” indicates there are conflicting, insufficient, or only preliminary studies suggesting a health benefit or that the health benefit is minimal. “Other” indicates that an herb is primarily supported by traditional use or that the herb or supplement has little scientific support and/or minimal proven health benefit.

References:

1. Dubey MP, Srimal RC, Nityanand S, Dhawan BN. Pharmacological studies on coleonol, a hypotensive diterpene from *Coleus forskohlii*. *J Ethnopharmacol* 1981;3:1–13.
2. Seamon KB, Daly JW. Forskolin: A unique diterpene activator of cAMP-generating systems. *J Cyclic Nucleotide Res* 1981;7:201–24 [review].
3. Wysham DG, Brotherton AF, Heistad DD. Effects of forskolin on cerebral blood flow: Implications for the role of adenylate cyclase. *Stroke* 1986;17:1299–303.
4. Marone G, Columbo M, Triggiani M, et al. Forskolin inhibits the release of histamine from human basophils and mast cells. *Agents Actions* 1986;18:96–9.
5. Roger PP, Servais P, Dumont JE. Regulation of dog thyroid epithelial cell cycle by forskolin, an adenylate cyclase activator. *Exp Cell Res* 1990;172:282–92.
6. Okuda H, Morimoto C, Tsujita T. Relationship between cyclic AMP production and lipolysis induced by forskolin in rat fat cells. *J Lipid Res* 1992;33:225–31.
7. Wong S, Mok W, Phaneuf S, et al. Forskolin inhibits platelet-activating factor binding to platelet receptors independently of adenylyl cyclase activation. *Eur J Pharmacol* 1993;245:55–61.
8. Agarwal KC, Parks RE. Forskolin: A potential antimetastatic agent. *Int J Cancer* 1983;32:801–4.
9. Caprioli J, Sears M. Forskolin lowers intraocular pressure in rabbits, monkeys and man. *Lancet* 1983;i:958–60.
10. Badian M, Dabrowski J, Grigoleit HG, et al. Effect of forskolin eyedrops on intraocular pressure in healthy males. *Klin Monatsbl Augenheilkd* 1984;185:522–6 [in German].
11. Kramer W, Thormann J, Kindler M, Schlepper M. Effects of forskolin on left ventricular function in dilated cardiomyopathy. *Arzneim Forsch* 1987;37:364–7.
12. Bauer K, Dietersdorfer F, Sertl K, et al. Pharmacodynamic effects of inhaled dry powder formulations of fenoterol and colforsin in asthma. *Clin Pharmacol Ther* 1993;43:76–83.
13. Bone K, Morgan M. *Clinical Applications of Ayurvedic and Chinese Herbs: Monographs for the Western Herbal Practitioner*. Queensland, Australia: Phytotherapy Press, 1996.
14. Bone K, Morgan M. *Clinical Applications of Ayurvedic and Chinese Herbs: Monographs for the Western Herbal Practitioner*. Queensland, Australia: Phytotherapy Press, 1996.

Copyright © 2000 Healthnotes, Inc. All rights reserved. www.healthnotes.com
1505 SE Gideon St., Suite 200, Portland, OR 97202

The information presented in *The Natural Pharmacy* is for informational purposes only. It is based on scientific studies (human, animal, or *in vitro*), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires August

2001

PROSECUTION HISTORY

2001-11-16 - Extension 2 granted

2001-10-30 - Extension 2 filed

2001-05-14 - Extension 1 granted

2001-04-30 - Extension 1 filed

2000-10-31 - Notice of allowance - mailed

2000-08-08 - Published for opposition

2000-07-07 - Notice of publication

2000-04-18 - Approved for Pub - Principal Register (Initial exam)

2000-04-14 - Case file assigned to examining attorney

CONTACT INFORMATION

Correspondent (Owner)

IMPACT NUTRITION, INC.

9928 E. ALABAMA DRIVE #1725

DENVER CO 80231

United States

Thank you for your request. Here are the latest results from the TARR web server.

This page was generated by the TARR system on 01/17/2002 14:54:13 ET

Serial Number: 75855039

Registration Number: (NOT AVAILABLE)

Mark (words only): DERMALEAN

Current Status: A request for the second extension of time to file a statement of use has been granted.

Date of Status: 2001-11-16

Filing Date: 1999-12-08

The Notice of Allowance Date is: 2000-10-31

Registration Date: (DATE NOT AVAILABLE)

Law Office Assigned: TMO Law Office 115

CURRENT APPLICANT(S)/OWNER(S)

1. IMPACT Nutrition, Inc.

Address:

IMPACT Nutrition, Inc.
9928 E. Alabama Drive #1725
Denver, CO 80231
United States

Country of Citizenship: United States

Incorporated in State: Colorado

Legal Entity Type: Corporation

GOODS AND/OR SERVICES

VITAMIN AND MINERAL FOOD SUPPLEMENTS

International Class: 005

First Use Date:

First Use in Commerce Date:

Basis: 1(b)

ADDITIONAL INFORMATION

(NOT AVAILABLE)

[STORE HOME](#) [TESTIMONIALS](#) [STORE SEARCH](#) [CHECK OUT](#) [FREE SAMPLES](#)

Toll Free Support 1-888

DermaLEAN™



What is DermaLEAN?
What are its benefits?
What are the benefits of transdermal application?
How does DermaLEAN compare to other weight-loss products?
Is this product legal?
Side effects?
Recommendations.

-ORDER NOW-

What is DermaLEAN?

DermaLEAN is the newest and most effective topical fat loss product available without a prescription. Most commonly found in European obesity clinics, DermaLEAN is used to break up fat pockets in cellulite specific areas of the body; hips, thighs, stomach buttocks, etc. Since it's recent awareness, the bodybuilding community is now generally using DermaLEAN for pre contest fat loss. It's applied very similarly to other pre-contest creams such as, Topical Triacana and the popular Thimucase. DermaLEAN is completely legal and sold as an OTC supplement in the U.S.

What are its benefits?

DermaLEAN will effectively and safely aid fat-loss to maintaining a healthy body-fat percentage. DermaLEAN contains ingredients to assist the break down body fat in troubled areas and ingredients to enhance well being riding stress related eating disorders, leading a happier healthier life.

What are the Ingredients?

Four Key Thermogenic Ingredients:

Aminophylline is a bronchiodilator commonly used in the treatment of asthma. It acts as a beta-2 adrenergic agonist, or activator of the beta-2 receptor in fat cells. Alpha and beta adrenergic receptors mediate very opposite effects on body fat, with beta-2 receptors being key triggers for lipolysis (fat loss). With this in mind aminophylline was investigated and shown to be highly successful as a topical fat loss crème in overweight women (1). This strategy was not novel however, as it was in fact already a well-tried practice to stimulate fat loss with the use of beta agonists such as ephedrine and clenbuterol, which are extremely popular with athletes and dieters due to their typically high level of positive response. Today there is little question that these types of substances can support the loss of body fat, and beta agonists in herbal form remain the most commonly used ingredients in OTC fat loss preparations.

Yohimbine is a potent alpha-2 adrenergic receptor antagonist, meaning that it works to block the activation of alpha adrenoceptors. As mentioned, alpha adrenoceptors have an opposite effect on the deposition of body fat compared to their beta counterparts. Alpha-2 receptors act to support fat storage, so blocking their activation can play a vital role in the stimulation of fat loss. The efficacy of yohimbine as a fat loss agent has clearly been demonstrated in a number of medical reports; including studies where it was given alone (2) or as a means to enhance lipolysis from concurrently administered beta agonists (3). Alpha-receptor antagonism is an important part of the fat loss puzzle, and may be too crucial to leave out of a well-planned diet program. For example, it is demonstrated that thigh fat is more difficult to mobilize than many other areas due to markedly higher concentrations of alpha-receptors in this region of the body (4).

Forskolin is the active ingredient in the *Coleus Forskohlii* root. *Forskohlii* is an herbal product originally used in India for medicinal purposes, and has only recently been discovered and utilized in the west as a fat loss agent. Forskolin plays a third and vital role in the stimulation of lipolysis; namely it increases cellular levels of cyclic AMP. Cyclic AMP is a messenger that mediates cellular activity, and it is well understood that cAMP can play a vital role in processes such as lipolysis. Forskolin is in fact well demonstrated to stimulate fat loss (5), and is crucial to DermaLEAN because it supports this process through a mechanism unique to the other two.

DMAE (2-dimethylaminoethanol) DMAE is a precursor to the brain chemical acetylcholine, which plays an important role in mood and well-being. It is also believed to be key in the CNS regulation of lipolysis and metabolism (6). Dieting is often believed to lower levels of acetylcholine in the brain, which in turn may work against the dieter by interfering with the normal regulation of metabolism and lipolysis, initiating a less positive outlook and agitating the need for feeding. Mental outlook is vital, as often it is the dieter's own inability to stick with a restricted caloric intake and exercise regimen that works against his or her progress. Although its effect is presumably not local, the addition of DMAE in DermaLEAN is still intended to support fat loss by helping to regulate normal brain control over tissue metabolism and lipolysis, as well as eliminate feelings of fatigue and disinterest in dieting. In essence, it works to bolster CNS functioning and the mental state of the user to strengthen the drive and likelihood of success during dieting.

-ORDER NOW-

What are the benefits of transdermal application?

Transdermal means transported through the skin. In other words, it's absorbed into the body through the skin. This is the most effective form of transport for this type of supplement. What makes it so effective? Because it's applied to the skin, DermaLEAN does not have to go through the digestion process that all oral supplements must go through. During digestion, oral supplements lose close to 95% of their active ingredients.

Another great benefit of transdermal application is its convenience. Oral supplements have a half-life of about 3 to 4 hours. This means that they need to be taken several times throughout the day to keep them consistently effective. With DermaLEAN, because it is a "time released" formula, one application per day (2ml) is sufficient to keep your metabolism at its optimum level throughout an entire 24-hour period. Not only is this more convenient, it is more efficient and easier on your body.

How does DermaLEAN compare to other weight-loss products?

DermaLEAN is quite possibly the most effective weight-loss product ever developed. Its proprietary compounds and transdermal delivery system have been administered by physicians for the treatment of cellulite and obesity for several years and has proven its effectiveness in the community. This combined with the fact that it's used only once daily makes DermaLEAN a superior and more convenient product.

Is this product legal?

Absolutely, we've had several communications with the FDA regarding the use of DermaLEAN and its ingredients. Under the DSHEA this product is completely legal.

Side effects?

Although uncommon, it is important to use only as directed and not to exceed 12 weeks of continuous use to help reduce the possibility of side effects occurring. Side effects associated with DermaLEAN are loss of appetite, tremors, dizziness, nervousness, restlessness, irregular heart beat, nausea, excessive sweating, diarrhea, and it is also possible to experience other complications due to the rapid weight loss or body-fat percentage loss that results from its use.

Recommendations.

To help utilize the effects of DermaLEAN, it is recommended that you apply it correctly, keep a healthy diet, and maintain a consistent workout regimen. Also stacking it with another weight-loss product like NitroPhen will help enhance its effects.

1. Apply it correctly: DermaLEAN works best when applied daily to area(s) in need of fat reduction. DermaLEAN is for topical use only and should not be injected or consumed.

2. Keep a healthy diet: Adjust your diet according to your personal goals. If you are trying to lose overall weight, keep a diet that is low in fat and useless calories. If you are trying to gain muscle and loose weight, keep a diet high in protein and complex carbohydrates. No matter what your goals are, to maintain your optimum metabolism, it is recommended that you drink a sufficient amount of water, get plenty of sleep (8 hours), and eat six small meals a day.

3. Maintain a consistent workout regimen: Being consistent in your strength training is a key element to producing quality muscle or losing weight. Make a schedule and stick to it. It's important to get plenty of rest and separate your strength from your aerobic training. This will help prevent over training.

DermaLEAN is not recommended for people under the age of 21. Do not use DermaLEAN if you have any pre-existing medical condition or if you are on any prescription medications unless a physician is consulted first.

-ORDER NOW-

©2001 AnabolicStore.com
all rights reserved

WEST**End of Result Set**

Generate Collection

L21: Entry 1 of 1

File: DWPI

Mar 22, 1990

DERWENT-ACC-NO: 1992-067087

DERWENT-WEEK: 199209

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Carnitine and its derivs. for cellulite treatment - NoAbstract

PATENT-ASSIGNEE:

ASSIGNEE

CODE

CAPORESE G

CAPOI

PRIORITY-DATA: 1988IT-0020483 (May 6, 1988)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

IT 1217516 B

March 22, 1990

000

APPLICATION-DATA:

PUB-NO

APPL-DATE

APPL-NO

DESCRIPTOR

IT 1217516B

May 6, 1988

1988IT-0020483

INT-CL (IPC): A61K 0/00

ABSTRACTED-PUB-NO:

EQUIVALENT-ABSTRACTS:

TITLE-TERMS: CARNITINE DERIVATIVE CELLULITE TREAT NOABSTRACT

DERWENT-CLASS: B05

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1992-030630

WEST

☐ Generate Collection

L14: Entry 48 of 66

File: DWPI

Sep 12, 2000

DERWENT-ACC-NO: 1998-041861

DERWENT-WEEK: 200050

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Inhibiting UV-induced skin damage e.g. photo-carcinogenesis and ageing -
comprises topical application of genistein i.e. di:hydroxy-(hydroxyphenyl-
)-benzopyranone

INVENTOR: WEI, H

PATENT-ASSIGNEE:

ASSIGNEE

MOUNT SINAI SCHOOL MEDICINE

MT SINAI SCHOOL MEDICINE CITY NEW YORK

CODE

MOUN

MOUN

PRIORITY-DATA: 1996US-0657915 (June 7, 1996)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2000511907 W	September 12, 2000		019	A61K007/00
WO 9746208 A2	December 11, 1997	E	017	A61K000/00
AU 9737225 A	January 5, 1998		000	A61K047/00
US 5824702 A	October 20, 1998		000	A61K031/35
EP 918504 A2	June 2, 1999	E	000	A61K007/42
AU 716131 B	February 17, 2000		000	A61K047/00

DESIGNATED-STATES: AU CA GB IL JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT
SE AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
JP2000511907W	June 9, 1997	1997WO-US11963	
JP2000511907W	June 9, 1997	1998JP-0500949	
JP2000511907W		WO 9746208	Based on
WO 9746208A2	June 9, 1997	1997WO-US11963	
AU 9737225A	June 9, 1997	1997AU-0037225	
AU 9737225A		WO 9746208	Based on
US 5824702A	June 7, 1996	1996US-0657915	
EP 918504A2	June 9, 1997	1997EP-0934083	
EP 918504A2	June 9, 1997	1997WO-US11963	
EP 918504A2		WO 9746208	Based on
AU 716131B	June 9, 1997	1997AU-0037225	
AU 716131B		AU 9737225	Previous Publ.
AU 716131B		WO 9746208	Based on

INT-CL (IPC): A61K 0/00; A61K 7/00; A61K 7/42; A61K 7/48; A61K 31/00; A61K 31/35;
A61K 31/352; A61K 35/78; A61K 47/00; A61P 17/00; A61P 43/00

ABSTRACTED-PUB-NO: US 5824702A

BASIC-ABSTRACT:

Inhibiting the harmful effect of UVR (ultraviolet radiation) exposure to the human skin comprises topical application of genistein (I) (i.e. 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one).

USE - (I) is applied to the skin at a time close to the time of UVR exposure to inhibit UV-induced skin damage, especially photo-carcinogenesis or photo-ageing. (I) is applied in amount at least 0.1 mu mol/cm2.

ADVANTAGE - (I) is a topical chemopreventative agent obtained from natural sources (soy products) and having no observed adverse effects or toxicities in humans. It has high lipid solubility, easily penetrates the skin and has potent and stable antioxidant activity.

ABSTRACTED-PUB-NO:

WO 9746208A

EQUIVALENT-ABSTRACTS:

Inhibiting the harmful effect of UVR (ultraviolet radiation) exposure to the human skin comprises topical application of genistein (I) (i.e. 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one).

USE - (I) is applied to the skin at a time close to the time of UVR exposure to inhibit UV-induced skin damage, especially photo-carcinogenesis or photo-ageing. (I) is applied in amount at least 0.1 mu mol/cm2.

ADVANTAGE - (I) is a topical chemopreventative agent obtained from natural sources (soy products) and having no observed adverse effects or toxicities in humans. It has high lipid solubility, easily penetrates the skin and has potent and stable antioxidant activity.

CHOSEN-DRAWING: Dwg.0/5

TITLE-TERMS: INHIBIT ULTRAVIOLET INDUCE SKIN DAMAGE PHOTO AGE COMPRISE TOPICAL APPLY DI HYDROXY HYDROXYPHENYL BENZOPYRANONE

ADDL-INDEXING-TERMS:
ULTRAVIOLET RADIATION

DERWENT-CLASS: B02 D21 E13

CPI-CODES: B06-A01; B14-R05; D08-B09A; D09-E; E06-A01;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

D013 D023 D120 G013 G100 H4 H403 H443 H8 J5
J521 M1 M113 M280 M320 M412 M511 M520 M531 M540
M781 M903 M904 P943 Q263

Specific Compounds

11605U

Chemical Indexing M3 *01*

Fragmentation Code

D013 D023 D120 G013 G100 H4 H403 H443 H8 J5
J521 M1 M113 M280 M320 M412 M511 M520 M531 M540
M781 M903 M904 P943 Q263

Specific Compounds

11605U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1998-013954